Clinical Trial Update: Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of CG0070 for high-grade non-muscle invasive bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• CG0070

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Bladder Cancer, High Grade | Phase 2 | Status: WITHDRAWN